Endocrinology

Latest News

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit  ©Tada Images/stock.adobe.com
Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

November 1st 2024

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose / image credit: ©New Africa/AdobeStock
Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose

November 1st 2024

GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D / Image credit: American College of Gastroenterology (ACG)
GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D

October 31st 2024

Semaglutide Linked with Reduced Risk of Alzheimer Disease in Large Observational Study / image credit Rong Xu, PhD  Courtesy Case Western Reserve University
Semaglutide Linked with Reduced Risk of Alzheimer Disease in Large Observational Study

October 25th 2024

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024 / Image credit: ©Rasi/AdobeStock
New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

October 23rd 2024

Latest CME Events & Activities
© 2024 MJH Life Sciences

All rights reserved.